GlobeNewswire by notified

Novartis highlights depth of immunology pipeline with novel data at key upcoming international congresses

  • Pivotal results for efficacy and safety of Cosentyx® (secukinumab) in hidradenitis suppurativa from Phase III SUNSHINE and SUNRISE trials to be debuted as late-breaker at European Academy of Dermatology and Venereology (EADV) Congress
  • Phase IIb data on remibrutinib (LOU064), an oral Bruton’s tyrosine kinase inhibitor, for people living with chronic spontaneous urticaria to be highlighted at EADV
  • Results of analysis at Week 52 from Phase IIb trial of ianalumab (VAY736), a dual mode of action B-cell activating factor receptor inhibitor in Sjögren’s syndrome, to be unveiled at International Symposium on Sjögren’s Syndrome
  • Total of 37 abstracts across both meetings will be presented, reflecting Novartis ambition to improve the lives of those affected by a range of immunological diseases

Basel, September 2, 2022 — Novartis today announced it will showcase data from its leading immunology portfolio and emerging pipeline at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress and the 15th International Symposium on Sjögren’s Syndrome (ISSS), both occurring September 7–10, 2022. A total of 37 abstracts will be shared across both meetings, spanning hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU), Sjögren’s syndrome, axial spondyloarthritis, and psoriasis.

“These data – including late-breaking results from our pivotal trials for Cosentyx® in hidradenitis suppurativa – demonstrate both the strength of our portfolio, and our commitment to pioneering the medicines of tomorrow in immunology,” said Angelika Jahreis M.D., Ph.D., FAAD, Global Head Development Unit Immunology and Clinical Development Excellence, Novartis. “We are focusing our development efforts on immunological diseases with significant unmet need, and hope that we will soon be able to provide more treatment options to patients to manage their conditions.”

The Novartis ambition is to reduce the suffering from immunological conditions, which affect up to 4.5% of the world’s population and can have a significant impact on quality of life1. In addition to its comprehensive portfolio of innovative therapy options, Novartis is exploring potential biologic and oral treatments with various mechanisms of action in HS, developing medicines that could help those living with CSU achieve complete symptom control, and advancing research in Sjögren’s syndrome, for which there are currently no disease-modifying treatments available2,3.

To assess and elevate the patient perspective at every stage of its clinical research, Novartis will also share the latest findings from a number of patient-based initiatives at EADV, including the global Psoriasis and Beyond study exploring the impact of psoriatic disease on mental health. Results from a comprehensive social media monitoring program to help illuminate the significant unmet needs of people living with HS will also be presented.

Highlights at ISSS

MedicineDisease areaAbstract titleAbstract number/ presentation details
Ianalumab (VAY736)Sjögren’s syndromeIanalumab (VAY736) Safety and Efficacy in Patients with Sjögren’s Syndrome: 52 Week Results from a Randomized, Placebo-controlled, Phase 2b Dose-ranging TrialAbstract ID119/
oral presentation/ September 9,

Highlights at EADV

MedicineDisease areaAbstract titleAbstract number/ presentation details
CosentyxHidradenitis suppurativa Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis from the SUNSHINE and SUNRISE Phase 3 Trials Abstract LB3549/
oral presentation/ September 10, 2022, 08:30–08:45

Late-breaking presentation
Cosentyx Hidradenitis suppurativaBaseline Characteristics and Subtype Clusters in Hidradenitis Suppurativa: Exploratory Analysis of SUNSHINE and SUNRISE StudiesAbstract P0040/
poster presentation/ September 7, 2022, 07:00

Cosentyx PsoriasisSecukinumab Demonstrates Superiority over Narrow-Band Ultraviolet B Phototherapy in New-Onset Moderate to Severe Plaque Psoriasis Patients: Week 52 Results from the STEPIn StudyAbstract P1518/
poster presentation/ September 7, 2022, 07:00
CosentyxPsoriasis Secukinumab Treatment Interruption Does Not Impact Effectiveness in Patients with Moderate to Severe Plaque Psoriasis: Results from an Interim Analysis of the SERENA StudyAbstract P1520/
poster presentation/ September 7, 2022, 07:00
CosentyxSpondyloarthritisHumoral Immunogenicity to Second and Third Doses of COVID-19 Vaccine BNT162b2 in Patients with Spondyloarthritis Receiving Secukinumab: A Prospective StudyAbstract P0584/
poster presentation/ September 7, 2022, 07:00

Remibrutinib (LOU064)

Chronic spontaneous urticariaRemibrutinib Demonstrates Faster Time to Complete Urticaria Control in Patients with Chronic Spontaneous Urticaria Compared with PlaceboAbstract P1726/
poster presentation/ September 7, 2022, 07:00

Remibrutinib (LOU064)

Chronic spontaneous urticariaLong-Term Safety and Tolerability of Remibrutinib (LOU064) in Phase 2b Study in Chronic Spontaneous Urticaria PatientsAbstract P1722/
poster presentation/ September 7, 2022, 07:00

Patient study
Chronic urticariaUrticaria Voices: Design of a Real-World Study on the Burden of Chronic Urticaria from Patients’ and Physicians’ PerspectivesAbstract P1739/
poster presentation/ September 7, 2022, 07:00
Patient studyPsoriatic diseaseImpact of Psoriatic Disease on Mental Health: Results from the Global Psoriasis and Beyond StudyAbstract FC06.08/
oral presentation/ September 10,

Patient study  Hidradenitis suppurativaUnderstanding the Real-World Patient Journey and Unmet Needs of Patients with Hidradenitis Suppurativa through Social Media MonitoringAbstract FC08.02/
oral presentation/ September 10,

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis in Immunology
Novartis aims to improve outcomes and enhance the lives of those affected by painful and debilitating immunological conditions. As a result, we have already helped transform the standard of care for children and adults suffering from conditions such as psoriatic disease and axial spondyloarthritis with Cosentyx®, chronic urticaria with Xolair®, and a number of rare autoinflammatory diseases with Ilaris®. We continue to focus on discovering and delivering innovative medicines for complex, less-explored immunological diseases where there is significant unmet need, such as hidradenitis suppurativa and Sjögren’s syndrome, lupus and osteoarthritis.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at

Novartis is on Twitter. Sign up to follow @Novartis at
For Novartis multimedia content, please visit

For questions about the site or required registration, please contact


1.  Scientific American. The Terrible Toll of 76 Autoimmune Diseases [online]. Available from: [Last accessed: August 2022].
2.  Sjögren's Foundation. Understanding Sjögren's - Symptoms [online]. Available from: [Last accessed: August 2022].
3.  NHS. Treatment - Sjögren's syndrome [online]. Available from: [Last accessed: August 2022].

# # #

Novartis Media Relations

Michael Meo
Novartis US External Communications
+1 862 274 5414 (direct)

Julie Masow
Novartis US External Communications
+1 862 579 8456
Rachel Fink-Thoma
Novartis Pharmaceuticals Communications
+41 613 248 245 (direct)

Novartis Investor Relations
Central investor relations line: +41 61 324 7944

CentralNorth America
Samir Shah+41 61 324 7944Sloan Simpson+1 862 345 4440
Nicole Zinsli-Somm+41 61 324 3809Alina Levchuk+1 862 778 3372
Isabella Zinck+41 61 324 7188Parag Mahanti+1 973-876-4912
To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Unplugged Performance Introduces UP INVINCIBLE®: A Game-Changer for Tesla Cybertruck Enthusiasts2.12.2023 05:06:20 CET | Press release

HAWTHORNE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Unplugged Performance, the industry leader in performance upgrades for Tesla vehicles, debuts a new chapter in Tesla tuning with the arrival of their UP INVINCIBLE® product line. UP INVINCIBLE® is tailored exclusively for Tesla Cybertruck owners who want to push the limits of on-road and off-road performance. The unveiling took place at Unplugged Performance’s celebratory afterparty for Tesla's highly anticipated Cybertruck delivery event on November 30th. Hosted at the company's headquarters in Hawthorne, California, neighboring Tesla Design Studio, SpaceX, and Starlink, the event drew a capacity crowd, reflecting the immense enthusiasm for this innovative product range. UP INVINCIBLE® represents a concerted effort to harness and amplify the rugged DNA of the Cybertruck, making it even more robust and capable in a variety of challenging environments. During the event, Ben Schaffer, CEO of Unplugged Performance, presented an extensiv

Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA2.12.2023 04:39:35 CET | Press release

SHANGHAI, China, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Therapeutic Goods Administration of the Australian Government Department of Health and Aged Care (TGA) has accepted the New Chemical Entity (NCE) application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. Additionally, the TGA has also granted an orphan drug designation to toripalimab for the treatment of NPC. This NCE application was submitted through Project Orbis, an initiative of

Terra Balcanica Announces Private Placement Financing1.12.2023 23:00:00 CET | Press release

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA) announces the intent to complete a non-brokered, private placement (“Private Placement”) for gross proceeds of up to $150,000 through the issuance of up to 3,750,000 common shares (“Common Shares”) at a purchase price of $0.04 per share. The Common Shares will be offered by way of prospectus exemptions in Canada and the Common Shares sold in the Private Placement will be subject to a hold period of four months plus one day. The Closing Date is expected to occur on or about December 11th, 2023, subject to regulatory approvals, including the approval by the CSE and certain other customary conditions including, but not limited to, execution of subscription agreements between the Company and the subscribers. The Private Placement will be utilized for opportuniti

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release

Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu

Havila Kystruten AS: Regnskap for tredje kvartal 20231.12.2023 18:34:33 CET | Pressemelding

September var første måned med full drift av alle fire skip. Til tross for forsinkelse av Havila Polaris og Havila Pollux i Q3, ble gjennomsnittlig belegg 70 % og gjennomsnittlig lugarrate kr 4 466. Inntektene er naturligvis preget av forsinkelsene og lavere enn forventet, men selskapet ser en positiv inntektsutvikling fra 2. kvartal og videre ut året. I forbindelse med refinansiering er driftskostnadene påvirket av ekstraordinære kostnader knyttet til juridiske og finansielle rådgivere. Regnskap og balanse påvirkes av valutasvingningene, og selskapet sikrer sine valutaforpliktelser med salg i valuta. Selskapet legger til grunn en normalisert drift av fire skip fremover, uten ekstraordinære kostnader. Selskapet har ambisjoner om et gjennomsnittlig belegg på 80 % for 2024, hvorav 45 % av all kapasitet allerede er solgt. Interessen for Havila Kystruten øker stadig i både inn- og utland, og positive tilbakemeldinger om produkt og konsept mottas på daglig basis. Resultat for 3. kvartal 202